CHE vs MANE
Chemed Corp. vs Veradermics, Incorporated — AI-powered side-by-side comparison
VS
MANE
Veradermics, Incorporated
67
Buy
| Metric | CHE | MANE |
|---|
| AI Score |
64
|
67
|
| Price |
$538.20
|
$111.00
|
| P/E Ratio |
27.16×
|
-69.90×
|
| ROE |
27.1%
|
57.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
30.4%
|
0.0%
|
| Debt / Equity |
0.40×
|
0.00×
|
| Dividend Yield |
0.4%
|
0.0%
|
| RSI (14) |
59.0
|
48.6
|
| Beta |
0.511
|
1.3492
|
| Expected Upside |
+3.3%
|
+6.7%
|
AI Committee View
Current Innellis committee reasoning for CHE versus MANE.
MANE leads by 3 points.
MANE scores 67/100 (Buy) versus CHE at 64/100 (Buy).
CHE Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 25.7 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.4% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 25.7 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
MANE Committee View
80% agreement
5 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical